Corynex is a novel Protein Expression system that overcomes some of the most frustrating challenges with common microbial expression systems by secreting fully folded and active proteins directly into the cell medium with minimal host proteins and impurities. This greatly simplifies the entire purification process, lowers costs, and ultimately speeds time to market.

1. Corynex®
A New Solution to Protein Expression
1

2. 2
biologic
medicines
large molecules made
in living organisms to
produce proteins
which treat diseases
Biologics offer treatments for some of the most challenging diseases including cancer,
HIV/AIDS, Alzheimer’s disease, and more.
By reconstructing segments of DNA, researchers are able to produce the desired proteins
(recombinant proteins), which target a specific disease.
Worldwide nearly 200 biologic
medicines have transformed the
lives of over 800 million
patients with serious diseases.
Protein Expression Systems are how these proteins are produced.

3. What is a Protein Expression System?
Protein Expression Systems refer to the type of living organism that
is used to grow the desired protein.
3
The most common
expression systems
for recombinant
biopharmaceuticals
are:
Each system varies with
respect to protein quality,
cost, expression amount,
and speed.

4. Microbial Expression Systems
Advantages:
• Affordable
• Easy to Culture
• Grow Fast
• High Titer
Drawbacks:
• Low Purification Yield
• Misfolded Protein
• Aggregation
• Protein Degradation
• Denaturation
• Cost/Time of purification
4

5. Is there a Solution?
5
Yes!
Corynex® is a
breakthrough, patented
system that overcomes
common challenges
with conventional microbial
expression systems by
allowing for:
• Isolation of higher yields
• Biologically active proteins
• Accurate folding
• Fewer host proteins
• Increased purity
• No endotoxins

6. So what exactly is Corynex?
Corynex uses the strand of bacterium,
Corynebacterium glutamicum to
produce these complex and difficult-to-express
proteins
Corynebacterium glutamicum:
Discovered in Japan (1956) as a producer of amino
acids for food production
Gram-positive soil bacterium
Generally Regarded as Safe (GRAS)
Ajinomoto Althea discovered it can express
therapeutic proteins  tremendous biopharma
impact
6
Non-sporulating, non-pathogenic, non-endotoxic

7. How does Corynex® work?
7
Promoter Target protein DNA
Target protein
Transformation Cultivation
Recombinant
Corynebacterium glutamicum
Plasmid vector
Signal peptide
Corynebacterium
glutamicum
Secretion
Corynex®
transforms
Corynebacterium
glutamicum with
DNA plasmids
containing the target
recombinant gene.
This gene is transcribed
using RNA polymerase
producing an mRNA
message. The mRNA
message is bound to a
ribosome complex and
begins translation into
an unfolded protein
molecule containing a
unique peptide signal
sequence.
These protein
molecules begin
accumulating in
the
Corynebacterium
glutamicum
cytoplasm before
they are ready for
secretion.
The proteins are
then secreted
though one of 2
pathways: SEC
pathway and TAT
pathway, and
accurately fold
directly in the
media.
Step 1 Step 2 Step 3 Step 4

8. Corynex Process
8
IGF-1
Fermentation
Separation
Chromatography
IGF-1
Fermentation
Separation Lysis Separation
Refolding
Chromatography
IGF-1 production
process using E.coli
IGF-1 production
process using Corynex®

9. Corynex Track Record
(since2009)
• 7 out of the Global Top 20 Pharma
• Licensed by a Big Pharma company
• Mid-size Pharma, Ventures etc.
• USA, Europe, Japan, Asia
Number of Customers:
>50 companies
Trial Expression:
>150 proteins
• Therapeutic proteins, reagent proteins,
enzymes etc.
Expression success rate:
>40%
• Impressive considering Corynex is often tried
when others have failed.
• SEC pathway, TAT pathway, Fusion method
• Improved success rate by utilizing all 3 methods
Process Development:
>10 proteins
• Over 10 proteins have gone through entire
process development stages
9

10. So Why Look into Using Corynex?
10
Secretes protein directly into media
No need for cell disruption
High initial purity
Less purification steps
Proteins already in active form
No need for refolding
For our customers  less downstream costs
~50 - 90% of manufacturing costs of biologics related to downstream
To learn more contact
Althea at
altheatech.com/contact